Hepatitis C, or viral hepatitis C, is a relatively common infectious liver disease with serious consequences if left untreated. If actively treated, the vast majority of patients can achieve a complete cure. According to current research, when the human body suffers from hepatitis C, without treatment, 15%-45% of acutely infected patients can spontaneously clear the virus six months after infection with hepatitis C virus, while the remaining 55%-85% of acutely infected patients may turn into chronic hepatitis C or carriers. At the chronic hepatitis C stage, if patients do not receive antiviral treatment, they may develop cirrhosis and liver cancer, at which time the condition is more serious and will affect the survival period of the patients. In view of the fact that more patients become chronic after hepatitis C virus infection, it is necessary to actively carry out antiviral treatment after hepatitis C virus infection is detected, no matter whether the infection is acute or chronic, and no matter whether there is any damage to the liver or whether the patient is a carrier of the virus. Usually, interferon combined with ribavirin can be applied to treat the disease, or a new type of oral antiviral drug can be applied to treat the disease. With active and effective treatment, the vast majority of patients can be completely cured and will not develop into cirrhosis or liver cancer.